AN2 Therapeutics (ANTX) Common Equity (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Common Equity data on file, last reported at $81.8 million in Q1 2026.

• On a quarterly basis, Common Equity rose 11.5% year-over-year to $81.8 million in Q1 2026; TTM through Mar 2026 was $81.8 million, a 11.5% increase from a year earlier, with the FY2025 full-year figure at $53.1 million, down 35.17% from the prior year.
• Common Equity for Q1 2026 stood at $81.8 million, up from $53.1 million in the prior quarter.
• Over the last five years, Common Equity for ANTX reached as high as $139.0 million in Q3 2023 and fell as low as $53.1 million in Q4 2025.
• Historically, Common Equity has averaged $93.1 million across 5 years, with a median of $87.8 million in 2023.
• Across the five-year window, Common Equity soared 599.31% in 2022 and sank 36.91% in 2024, its largest moves.
• Year by year, Common Equity stood at $95.4 million in 2022, then soared by 30.75% to $124.7 million in 2023, then slumped by 34.36% to $81.8 million in 2024, then sank by 35.17% to $53.1 million in 2025, then jumped by 54.09% to $81.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $81.8 million in Q1 2026, $53.1 million in Q4 2025, and $60.4 million in Q3 2025.